ECO ANIMAL HEALTH GROUP PLC

Report Publication Announcement • Jan 24, 2022

National Storage Mechanism | Additional information

RNS Number : 2829Z

Eco Animal Health Group PLC

24 January 2022

ECO Animal Health Group plc

(''ECO" or "the ECO Group") (AIM: EAH)

Investor Presentation

ECO Animal Health Group plc (AIM: EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that Marc Loomes, CEO, Christopher Wilks, CFO, and Hafid Benchaoui, Global Head of R&D, will be conducting a live presentation following their Capital Markets Day to institutional investors at 9am.

The online presentation will take place on Wednesday 26th January at 2.30pm London time.

ECO started a programme of significant R&D investment in vaccines around four years ago and has seen meaningful progress. This event will be an opportunity for investors to hear insights from the management team and further details of the potential commercial value that exists within the new product development pipeline.

The presentation is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end.

To register for the online event, please go to: https://www.equitydevelopment.co.uk/news-and-events/ecoanimalhealth-investorspresentation-26jan

A recording of the presentation will be available shortly after the event.

Contacts:

ECO Animal Health Group plc Marc Loomes (CEO) Chris Wilks (FD)	020 8447 8899
IFC Advisory Graham Herring Zach Cohen	020 3934 6630
Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas	020 7496 3000
Investec (Joint Broker) Gary Clarence Alex Penney Carlo Spingardi Peel Hunt LLP (Joint Broker) Dr Christopher Golden James Steel	020 7597 5970 020 7418 8900

Equity Developments Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUAUVRUSUAUAR